Abbott Labs shares pop as revenue, earnings defy steep drop in Covid test sales

[ad_1] The Abbott manufacturing facility in Sturgis, Michigan, on May 13, 2022. Jeff Kowalsky | AFP | Getty Images Shares of Abbott Laboratories popped Wednesday after the company’s earnings and revenue topped Wall Street’s expectations, defying a dramatic slowdown in sales of its Covid-19 tests.  The medical-products company posted adjusted earnings per share of $1.03….

Read More

Johnson & Johnson shares fall after company beats on earnings and revenue, but lowers pharmaceutical sales guidance

[ad_1] Johnson & Johnson shares fell Tuesday after the company reported adjusted earnings and revenue that topped Wall Street’s expectations, but lowered its sales guidance for its pharmaceutical business. J&J, whose financial results are considered a bellwether for many health companies, said its sales during the quarter grew 5.6% over the same quarter last year.  related…

Read More

FDA authorizes additional omicron Covid booster for seniors and people with weak immune systems

[ad_1] Sylvester Fisher gets a influenza vaccine from pharmacist Patricia Pernal during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center on September 09, 2022 in Chicago, Illinois. The vaccines were being offered along with pneumonia vaccines and the recently authorized COVID-19 booster vaccine, which protects against the original…

Read More

Supreme Court lifts abortion pill restrictions for now

[ad_1] U.S. Supreme Court Justice Samuel Alito on Friday temporarily blocked lower court rulings that imposed tighter restrictions on the abortion pill mifepristone. U.S. Judge Matthew Kacsmaryk of the U.S. Northern District of Texas suspended the Food and Drug Administration’s approval of mifepristone last week. related investing news The U.S. 5th Circuit Court of Appeals…

Read More

Abortion providers rush to make backup plans as Supreme Court decides whether to keep limits on mifepristone

[ad_1] U.S. abortion pill providers are scrambling to make backup plans as the Supreme Court decides whether to keep restrictions on the key drug mifepristone.  Some in-person clinics in New York, California and Kansas will offer mifepristone for now, but are preparing to provide an alternative abortion pill if a subsequent decision essentially bans the…

Read More